Human Cloning Company Hit Hard Times, Sells Experiments for Parts

PALO ALTO, CA - Clonia, a biomedical firm specializing in research into humoan cloning, has announced that due to a tight credit market and lackluster investor activity it will be forced to sell some of its experiments for parts in order ot further its research. The firm says the bad economy has hurt it sales potential as affluent people hold back spending on clones for heirs or organs.

"The collapse of the banking system and subsequent recession have hurt our cash flow, and in order to make up for the losses we must sell off inventory and a low price," said Dr. Richard Harper, CEO of Clonia.

Harper said that the experimental clones are usually donated to UCLA Medical School for the tax write-off, but now they may be the sole source of revenue to keep the company afloat.

Cloning researcher Alana Fox of MIT, who is not connected to the company, said that there is a risk of complication from cloned organs, but they can be safer from other alternatives.

"Clones being chop-shopped into organs had some problems associated with them. Sometimes it's one organ system failure, sometimes unknown. But if the medical history of the clone is well documented the problems can be mitigated. It's certainly better than buying Chinese organs on the black market, since those almost certainly contian lead," Fox said.